Abstract
Bombesin-like peptides (BLP) and its receptors are widely distributed in mammalian peripheral tissues and in the central nervous system. Recently, effects of these peptides on the production and release of cytokines were described both in animal models and humans with inflammatory diseases. Some pathological conditions such as exposure to tobacco smoke, chronic obstructive pulmonary diseases and eosinophilic granuloma have recently been found to be associated with an increase of pulmonary BLP-producing cells. Proinflammatory neuropeptides have a key role in the pathogenesis and maintenance of rheumatoid arthritis and sepsis. Together, these findings support the view that the GRPR should be considered a therapeutic target for a subset of inflammatory diseases.
Keywords: Neuropeptide, bombesin-like peptides, gastrin-releasing peptide receptor, immune system, sepsis
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Related Books
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
Anti-Obesity Drug Discovery and Development
4